Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Gilteritinib in R/R AML
NCT03625505Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Primary completion
- Aug 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax and gilteritinib in acute myeloid leukemia (AML) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Recommended Phase 2 Dose of Co-administered Study Drugs at 6 months and Modified Composite Complete Remission at 6 months. Started Oct 2018; status: completed.
02
Drugs
venetoclaxgilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03625505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625505.